Can this biopharmaceutical Company be a game changer amidst COVID-19: Veru Inc. (NASDAQ: VERU) ?

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer.

Veru’s breast cancer development portfolio includes:

• Enobosarm, a selective androgen receptor targeting agonist
• Sabizabulin, a cytoskeleton disruptor.

Veru’s prostate cancer development portfolio includes:

• VERU-100, a long-acting GnRH antagonist; and
• Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.

Highlights & News Update

• FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway

• Company Enters into Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate Enobosarm and Abemaciclib Combination in Phase 3 ENABLAR-2 Trial

• Phase 3 COVID-19 Registration Program Receives FDA Fast Track Designation, Clinical Results Expected in the First Half of Calendar 2022

• Company announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent will be presented at the 2022 ASCO Genitourinary Cancers Symposium being held February 17-19, 2022 in San Francisco, CA. Sabizabulin is an oral new chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt the cytoskeleton.

First Quarter 2022 Financial Highlights

• Net revenues climbed 27% to $11.6 million from $9.1 million
• Gross profit rose 9% to $11.8 million from $10.8 million
• Gross margin increased to 84% of net revenues from 74% of net revenues, a record high compared to any prior quarter
• Operating loss was $5.0 million compared with operating income of $19.2 million

Quick Look at last 4 years earning and forecast

Earnings

Forecast

Quick Look at company’s Key Data

Risk Factor

Veru is a small-cap biotech stock, and its shares are likely to remain volatile in the days and weeks ahead. But if Veru can obtain an EUA for sabizabulin, more gains could lie ahead for its shareholders.

Stock Recommendation

Global analysts rating on Veru and boosted their stock price forecast from $5 to $24. it was noted that the trial results suggest sabizabulin could reduce deaths in COVID-19 patients at high risk of acute respiratory distress syndrome (ARDS), which would differentiate it from other treatment options. In turn, Veru could generate a sizable amount of revenue from sabizabulin, should it receive authorization from the FDA.

MarketFacts gives a “Buy” rating on the stock at the closing Price of $4.79 USD as of April 5th, 2022.

CMP (USD) (5th April 2022)	$4.79
Target Price (USD)	$8.50
Recommendation	Buy